An oral @entity2936 ligand gene therapy against lymphoma using attenuated XXXX .

@entity2491 @entity1 @entity2937 @entity5 @entity7938 @entity19 @entity2936 @entity11603 @entity1892
@entity11603 ( @entity11603 ) has a great potential as a novel treatment for @entity1892 ( @entity1892 ). It has previously been demonstrated that a nonvirulent strain of @entity2491 mutant (ST) can be used not only as a vehicle in oral genetic immunization via the intestinal mucosa, but also as an enhancer of interferon gamma- and @entity5 necrosis factor alpha-mediated immunity. After confirming that @entity1 @entity11603 can up-regulate expression of Fas, @entity7938 , and @entity2937 molecules on @entity19 @entity1892 cells in vitro, we transfected the @entity1 @entity11603 gene into @entity2491 mutant (ST40L), which was administrated orally to determine whether it was able to prevent the growth of @entity1892 in @entity19 . Expression of @entity1 @entity11603 was confirmed immunohistochemically with protein being detected in the Peyer's patches of @entity19 immunized with ST40L. Moreover, @entity1 soluble @entity11603 had been detectable until 7 to 8 weeks after oral administration of ST40L. Although ST alone exhibited some protective effects, ST40L demonstrated a significantly greater protection against the development of @entity2936 positive @entity1892 compared with the control. In the surviving @entity19 that had been treated with ST40L, a small and hard nodule was formed at the injection site, which was found to be composed of infiltrating lymphocytes expressing Fas ligand. These results have the potential to be a simple, effective, and above all, safe immune-gene therapy against @entity1892 . (Blood. 2000;95:1258-1263)
